Crinetics Pharmaceuticals Announces Key Presentations at ENDO 2025

Details

announced that it will present eight abstracts from its clinical development programs at the Endocrine Society's Annual Meeting, ENDO 2025, in San Francisco, California, from July 12-15, 2025. The presentations will include long-term efficacy and safety data on PALSONIFY for acromegaly, Phase 2 trial results for atumelnant in congenital adrenal hyperplasia, and new data from an early-stage development program in Graves' hyperthyroidism and orbitopathy. The full press release is attached as Exhibit 99.1.

Items reported

Exhibits (1)

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.